Alterity Therapeutics Limited: February 2025 SEC Form 6-K Filing Insights

Here are the key insights extracted from the provided financial report (Form 6-K) related to Alterity Therapeutics Limited:

1. Filing Information:

• This is a Form 6-K filing, which is a report for a foreign private issuer to provide current information to the SEC.
• The report is filed under the Securities Exchange Act of 1934.

2. Date of Filing:

• The report is for the month of February 2025.

3. Company Details:

• Name: Alterity Therapeutics Limited
• Address: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
• It is indicated that the company is in the development stage.

4. Annual Report Filing:

• The registrant indicates that it will file annual reports under Form 20-F and not Form 40-F.

5. Incorporation by Reference:

• The Form 6-K is incorporated by reference into multiple Registration Statements on Form S-8 and Form F-3, which relate to securities offerings.
• Specific files referenced include:
• • Form S-8: 333-251073, 333-248980, 333-228671
  • Form F-3: 333-274816, 333-251647, 333-231417, 333-250076

6. Exhibit Submission:

• An exhibit (99.1) is included in the filing which pertains to a proposed issue of securities.

7. Signatory Information:

• The document is signed by Geoffrey P. Kempler, who is the Chairman of the company.
• The signature is dated February 24, 2025.

This report primarily serves to update the SEC on the company’s current status and intentions regarding securities, as well as confirming its compliance with regulatory requirements. The incorporation of this filing into other registration statements indicates ongoing capital raising efforts. The development-stage designation suggests that the company may still be in the process of commercializing its product or service offerings.